Enanta Pharmaceuticals (ENTA) FCF Margin (2012 - 2026)
Enanta Pharmaceuticals posted quarterly FCF Margin of 41.79% for Q1 2026, up 6558.0% year-on-year from 0.63% in Q1 2025, and up 34.31% on a QoQ basis from 63.62% in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of FCF Margin data on file, last reported at 41.79% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 6558.0% year-over-year to 41.79%; the trailing twelve-month figure through Mar 2026 stood at 13.88% (up 11369.0% YoY), and the FY2025 full-year result was 49.24%, up 9375.0% from the prior year.
- FCF Margin for Q1 2026 stood at 41.79%, up from 63.62% in the prior quarter.
- Across five years, FCF Margin topped out at 149.57% in Q2 2025 and bottomed at 181.45% in Q2 2023.
- The 5-year median for FCF Margin is 121.33% (2023), against an average of 108.31%.
- The widest annual swing landed in 2022, when FCF Margin slumped 11962 bps; it then soared 25383 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 164.5% in 2022, then rose by 13 bps to 143.17% in 2023, then decreased by 5 bps to 150.63% in 2024, then jumped by 58 bps to 63.62% in 2025, then soared by 34 bps to 41.79% in 2026.
- The last three FCF Margin figures came in at 41.79% (Q1 2026), 63.62% (Q4 2025), and 118.94% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -41.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.79% |
| Dec 31, 2025 | -63.62% |
| Sep 30, 2025 | -118.94% |
| Jun 30, 2025 | 149.57% |
| Mar 31, 2025 | -107.37% |
| Dec 31, 2024 | -150.63% |
| Sep 30, 2024 | -150.15% |
| Jun 30, 2024 | -104.26% |
| Mar 31, 2024 | -177.49% |
| Dec 31, 2023 | -143.17% |
| Sep 30, 2023 | -121.33% |
| Jun 30, 2023 | -181.45% |
| Mar 31, 2023 | -90.85% |
| Dec 31, 2022 | -164.50% |
| Sep 30, 2022 | -79.05% |
| Jun 30, 2022 | -153.26% |
| Mar 31, 2022 | -143.01% |
| Dec 31, 2021 | -48.17% |
| Sep 30, 2021 | -92.28% |
| Jun 30, 2021 | -135.05% |
| Mar 31, 2021 | -23.39% |
| Dec 31, 2020 | -47.50% |
| Sep 30, 2020 | -64.96% |
| Jun 30, 2020 | -25.08% |
| Mar 31, 2020 | 54.50% |
| Dec 31, 2019 | 22.59% |
| Sep 30, 2019 | 16.08% |
| Jun 30, 2019 | 0.68% |
| Mar 31, 2019 | 71.91% |
| Dec 31, 2018 | 41.42% |
| Sep 30, 2018 | 42.11% |
| Jun 30, 2018 | 9.14% |
| Mar 31, 2018 | -19.80% |
| Dec 31, 2017 | 11.28% |
| Sep 30, 2017 | 75.17% |
| Jun 30, 2017 | -73.72% |
| Mar 31, 2017 | -39.96% |
| Dec 31, 2016 | 21.04% |
| Sep 30, 2016 | 12.15% |
| Jun 30, 2016 | -19.49% |
| Mar 31, 2016 | 65.68% |
| Dec 31, 2015 | 57.38% |
| Sep 30, 2015 | -27.43% |
| Jun 30, 2015 | -125.90% |
| Mar 31, 2015 | 172.16% |
| Dec 31, 2014 | -7.57% |
| Sep 30, 2014 | -205.42% |
| Jun 30, 2014 | 82.60% |
| Mar 31, 2014 | -197.73% |
| Dec 31, 2013 | -660.13% |
| Sep 30, 2013 | -200.52% |
| Jun 30, 2013 | -362.28% |
| Mar 31, 2013 | 810.37% |
| Dec 31, 2012 | 32.43% |
| Sep 30, 2012 | -97.58% |
| Jun 30, 2012 | -152.44% |